Financials

  • Market Capitalization 333.49 M
  • Employee 35
  • Founded 2008
  • CEO N/A
  • Website www.inhibikase.com
  • Headquarter Delaware, United States
  • FIGI BBG005TP2339
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-4.61
Relación precio/flujo de caja
54.94

Related tickers

#NombrePrecio24h %7d %1M %1A %CapitalizaciónÚltimos 7 días
3192
FHTX
Foghorn Therapeutics Inc. - Common Stock
5.69 USD-0.87%-16.93%+25.05%+39.46%337.90 M USD
3194
SABS
SAB Biotherapeutics, Inc. - Common Stock
3.70 USD-0.27%-2.63%+3.06%+79.61%336.65 M USD
3244
VNDA
Vanda Pharmaceuticals Inc. - Common Stock
5.43 USD+0.56%-0.18%+6.47%-1.81%328.31 M USD
3249
IMRX
Immuneering Corporation - Class A Common Stock
4.85 USD-2.81%-7.27%+16.87%-14.01%313.78 M USD

Noticias